Insulin and Oral Agents for Managing Cystic Fibrosis-Related Diabetes

Background

The Cystic Fibrosis Foundation recommends both short‐term and long‐acting insulin therapy when cystic fibrosis‐related diabetes has been diagnosed. Diagnosis is based on: an elevated fasting blood glucose level greater than 6.94 mmol/liter (125 mg/deciliter); or oral glucose tolerance tests greater than 11.11 mmol/liter (200 mg/deciliter) at two hours; or symptomatic diabetes for random glucose levels greater than 11.11 mmol/liter (200 mg/deciliter); or glycated hemoglobin levels of at least 6.5%.
Objectives

To establish the effectiveness of insulin and oral agents for managing diabetes in people with cystic fibrosis in relation to blood sugar levels, lung function and weight management.
Search methods

We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also handsearched abstracts from pulmonary symposia and the North American Cystic Fibrosis Conferences.

Date of the most recent search of the Group's Cystic Fibrosis Trials Register: 18 February 2016.
Selection criteria

Randomized controlled trials comparing all methods of diabetes therapy in people with diagnosed cystic fibrosis‐related diabetes.
Data collection and analysis

Two authors independently extracted data and assessed the risk of bias in the included studies.